Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: mix (142), complex (150), composite (5), multiple (257), multifaceted (2)

Procedure for start-up, tuning and shut down of profile 3 SIFT FAMS analyser

Description: NIHR Southampton Biomedical Research Centre The NIHR Southampton Biomedical Research Centre (BRC) has a tight quality assurance system for the writing
Url: /Media/Southampton-Clinical-Research/Procedures/BRCProcedures/Procedure-for-start-up,-tuning-and-shut-down-of-profile-3-SIFT-FAMS-analyser.pdf

Haemochromatosis care pathway

Description: Hereditary Haemochromatosis Care Pathway Aim: Cascade test so that C282Y homozygotes and C282Y/H63D heterozygotes are identified Hereditary hae
Url: /Media/UHS-website-2019/Docs/Services/Genetics/General-genetics/Haemochromatosis-care-pathway.pdf

Press release: Southampton cancer nurse transforming care for military personnel and veterans

Description: A Southampton nurse who has transformed care for armed forces personnel and veterans diagnosed with an asbestos-related cancer has been
Url: /AboutTheTrust/Newsandpublications/Latestnews/2019/August/Press-release-Southampton-cancer-nurse-transforming-care-for-military-personnel-and-veterans.aspx

ARC SETT project EOI v2 final

Description: Building analytic capability to address compound pressure across health and care systems: testing an approach. Expression of interest: Operational modelling and
Url: /Media/Southampton-Clinical-Research/Downloads/ARC-SETT-project-EOI-v2-final.pdf

ACCORD-2 example sub-protocol

Description: CONFIDENTIAL ACCORD-2-002 - Sub protocol for Bemcentinib (Amendment 01) TITLE PAGE Master Protocol Title: ACCORD-2: A Multicentre, Seamless, Phase
Url: /Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-example-sub-protocol.pdf

Papers Trust Board - 11 November 2025

Description: Date Time Location Chair Agenda Trust Board – Open Session 11/11/2025 9:00 - 13:00 Conference Room, Heartbeat Education Centre
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/Papers-Trust-Board-11-November-2025.pdf

Topotecan (1,8,15)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER TOPOTECAN INTRAVENOUS (1, 8, 15) Regimen Ovary – Topotecan (1, 8, 15) Indication Second-line or subsequent treatment
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Topotecan1815.pdf

Topotecan (1,8)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER TOPOTECAN INTRAVENOUS (1, 8) Regimen Ovary – Topotecan (1, 8) Indication Second-line or subsequent treatment of platinum
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Topotecan18.pdf

Topotecan (1,2,3,4,5)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER TOPOTECAN INTRAVENOUS (1, 2, 3, 4, 5) Regimen Ovary – Topotecan (1, 2, 3, 4, 5) Indication Second
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Topotecan12345.pdf

Liposomal doxorubicin

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER LIPOSOMAL DOXORUBICIN (Caelyx) Please note this protocol is based on information for the use of the Caelyx
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Liposomaldoxorubicin.pdf

1 to 10 of 32

Previous 1 2 3 4 Next